Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
Hydrogels are biocompatible drug delivery systems by which the physical properties can be controlled by the cross-linking density. Hydrogels were prepared by copolymerization of acrylic acid monomers in the presence of poly(ethylene glycol)(PEG) to form polyethylene diacrylate (PEDGA). Various molecular weights of PEGs were used for the synthesis of PEGDA to study the effect of molecular weight of PEG on the properties of hydrogels. These hydrogels were further characterized for free water, swelling..


Pharmaceutical Technology


Absorbing water is one of the vital properties of hydrogels, because it makes them biocompatible (1). The water-absorbing capacity of hydrogels was determined in terms of percent equilibrium water content (% EWC) or swelling ratio (SR). The dry hydrogels were weighed (W d ) and then immersed in distilled water for 24 h at 37 2 C. The hydrogels then were reweighed (W s ) after removing the excess water by lightly soaking the swollen hydrogels using filter paper. The swelling ratio of the hydrogels was determined using the formula:













Water diffusion study. Release of the drug from a matrix system generally occurs by a diffusion mechanism. The drug diffuses out, along with water, in the form of a solution at pH 7.0 of the release medium. The water-diffusion study, therefore, is indirectly a measure of solute diffusion. It is assumed that diffusion from the matrices follows Fick's law of drug dissolution and diffusion in the medium, both during the sorption and desorption phenomenon (23). In the present study, the diffusion property of the hydrogels was studied using desorption phenomenon. The swollen hydrogels were dried gradually under air at room temperature and weighed after 15-min intervals until a constant weight was reached. The diffusion coefficients of the hydrogels were calculated using the equation:











in which, D is the diffusion coefficient of the hydrogel, δmt is the weight loss in t time, δmis the weight loss at infinity, l is the thickness of the dried hydrogel, and t is the time of diffusion of water from the hydrogels during drying.

Drug loading . The drug can be incorporated in the hydrogels by in situ drug-loading during polymerization and by drug-loading by incubation after polymerization (5). In the present experiment, diclofenac sodium was loaded by incubating a known weight of the hydrogel in a 10% w/v aqueous solution of the drug for 24 h at room temperature. The drug-loaded hydrogels then were dried and stored in a well-closed container for further use. The drug remaining in the incubating solution was determined spectrophotometrically at 276 nm after appropriate dilution. The entrapment efficiency of the hydrogel was calculated as follows:










in which, A o is the initial amount of drug in the incubation medium, A f is the final amount of drug in the incubation medium, and W h is the dry weight of the hydrogel incubated for drug loading.

Release kinetics and porosity. Release studies were carried out in distilled water as receptor medium, maintained at 37 2 C. Sink condition was continuously maintained. The amount of drug released in the dissolution medium was determined spectrophotometrically at 276 nm after every 1-h interval. The study was continued for 72 h. The data of release profiles for each formulation were analyzed further by model fitting with the help of software PCP DissoV2.5 (Pune College of Pharmacy, Pune, India).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here